Myeloproliferative neoplasms Archives

What drove Nathalie Cook to help list Pegasys on the PBS

Nathalie Cook OAM, who was diagnosed with MPN in 2008, tells the story of the delay in her diagnosis and how after attending a conference in the USA, on the flight home, she made the decision to try to get Pegasys on the Pharmaceutical Benefits Scheme for people with MPN in Australia. It took 7 years to achieve this goal and the hearing her share the story of how she made it happen is truly astounding.

Leukaemia
Myeloproliferative neoplasms

Living with PV has become “a normal way of life” for Debbie

When Debbie McFarlane was diagnosed with the myeloproliferative neoplasm (MPN), polycythaemia vera (PV) in 2013, she didn’t realise it was a form of blood cancer.

Myeloproliferative neoplasms

An antibody for myelofibrosis – “that’s a true discovery”

A new monoclonal antibody, discovered by accident by Adelaide researchers, could become the world’s first effective treatment for primary myelofibrosis (MF).

Myeloproliferative neoplasms

Expert Series: Prof. Wendy Erber – a tool predicting the potential progression of MPNs coming soon

Professor Wendy Erber and her research team in Western Australia are developing a monitoring tool they hope will identify MPN patients who will go on to develop leukaemia.

Interviews with experts
Myeloproliferative neoplasms
Research

Charlie’s blood cancer went undiagnosed for a decade

Myeloproliferative neoplasms

Expert Series: Professor Andrew Perkins on MPN

It’s emerging in all cancers, but particularly in the MPNs, that “genomics is everything” according to Professor Andrew Perkins, an expert in myeloproliferative neoplasms (MPN).

Interviews with experts
Myeloproliferative neoplasms
Research

Sharon’s 30 years living with MPN

Diagnosed with PV and ET at the age of 18, Sharon was having treatment when she fell pregnant with the first of her three healthy children in 2000.

Myeloproliferative neoplasms

Aim of first-ever CMML study – to improve survival

A lot of ‘world firsts’ are involved in an Australian clinical trial that is taking a precision medicine approach to treating CMML, a neglected and serious rare blood cancer that is poorly understood.